Abstract
Barrett's esophagus has been identified as the premalignant precursor of esophageal adenocarcinoma. The eradication of metaplastic or dysplastic columnar-lined (Barrett's) esophagus may prevent progression to esophageal adenocarcinoma. 5-Aminolevulinic acid photodynamic therapy is a simple method for the mucosal ablation of the abnormal segment. Areas of metaplastic epithelium may remain buried after treatment and continued surveillance is necessary. Repeated treatments often are necessary but are very well tolerated with few complications.
MeSH terms
-
Aminolevulinic Acid / administration & dosage
-
Aminolevulinic Acid / pharmacokinetics
-
Aminolevulinic Acid / therapeutic use*
-
Barrett Esophagus / drug therapy*
-
Barrett Esophagus / metabolism
-
Barrett Esophagus / pathology
-
Esophagoscopy
-
Humans
-
Injections, Intravenous
-
Intestinal Mucosa / drug effects
-
Intestinal Mucosa / metabolism
-
Intestinal Mucosa / pathology
-
Photochemotherapy / methods*
-
Photosensitizing Agents / administration & dosage
-
Photosensitizing Agents / pharmacokinetics
-
Photosensitizing Agents / therapeutic use*
-
Protoporphyrins / metabolism
-
Treatment Outcome
Substances
-
Photosensitizing Agents
-
Protoporphyrins
-
Aminolevulinic Acid
-
protoporphyrin IX